



PATENT
Our Docket: P-AR 4528

1653
#6
JUN 28 2001
TECH CENTER 1600/2900
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Klein et al.

Serial No.: 09/814,604

Filed: March 22, 2001

For: METHODS OF DETECTING
DISSOCIATED NUCLEAR
HORMONE RECEPTOR LIGANDS

)
) Examiner: Unassigned
)
) Group Art Unit: 1653

) I hereby certify that this correspondence
) is being deposited with the United States
) Postal Service as first class mail in an
) envelope addressed to: Commissioner for
) Patents, Washington, D.C., 20231, on
) June 22, 2001.

By Andrea L. Gashler
Andrea L. Gashler, Reg. No. 41,029

Commissioner for Patents
Washington, D.C. 20231

June 22, 2001
Date of Signature

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-0370.

Respectfully submitted,

Date: June 22, 2001

Andrea L. Gashler
Andrea L. Gashler
Registration No.: 41,029
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

Campbell & Flores LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601

Form PTO 1449 JUN 25 2001 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4528	SERIAL NO: 09/814,604
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Klein et al.	FILING DATE: March 22, 2001

U.S. PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)


<i>[initials]</i>	<i>[initials]</i>	Anzick et al., "AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer," <u>Science</u> 277:965-968 (1997)
<i>[initials]</i>	<i>[initials]</i>	Barroso et al., "Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension," <u>Nature</u> 402:880-883 (1999)
<i>[initials]</i>	<i>[initials]</i>	Berger et al., "A PPAR γ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus," <u>Mol. Cell. Endocrin.</u> 162:57-67 (2000)
<i>[initials]</i>	<i>[initials]</i>	Blanco et al., "The histone acetylase PCAF is a nuclear receptor coactivator," <u>Genes Devel.</u> 12:1638-1651 (1998)
<i>[initials]</i>	<i>[initials]</i>	Chakravarti et al., "Role of CBP/P300 in nuclear receptor signaling," <u>Nature</u> 383:99-103 (1996)
<i>[initials]</i>	<i>[initials]</i>	Chen and Evans, "A transcriptional co-repressor that interacts with nuclear hormone receptors," <u>Nature</u> 377:454-457 (1995)

EXAMINER 	DATE CONSIDERED 11.25.02
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


TECH CENTER 1600/2900

JUN 28 2001




Form PTO 1449	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4528	SERIAL NO. 09/814,604
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Klein et al.	GROUP: 1653
		FILING DATE: March 22, 2001	

✓	Chen et al., "RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation," <u>EMBO J.</u> 14:1187-97 (1995)
✓	Chen et al., "Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase," <u>Cell</u> 98:675-686 (1999)
✓	Enmark et al., "Orphan nuclear receptors--the first eight years," <u>Mol. Endocrinol.</u> 10:1293-1307 (1996)
✓	Fanjul et al., "A new class of retinoids with selective inhibition of AP-1 inhibits proliferation" <u>Nature</u> 372:107-111 (1994)
✓	Feng et al., "Suprabasal expression of a dominant-negative RXR α mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids," <u>Genes Dev.</u> 11:59-71 (1997)
✓	Glass and Rosenfeld, "The coregulator exchange in transcriptional functions of nuclear receptors," <u>Genes Dev.</u> 14:121-141 (2000)
✓	Gurnell et al., "A dominant-negative peroxisome proliferator-activated receptor gamma (PPAR γ) mutant is a constitutive repressor and inhibits PPAR γ -mediated adipogenesis," <u>J. Biol. Chem.</u> 275:5754-5759 (2000)
✓	Horlein et al., "Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor," <u>Nature</u> 277:397-404 (1995)
✓	Hu and Lazar, "The CoNR motif controls the recruitment of corepressors by nuclear hormone receptors," <u>Nature</u> 402:93-96 (1999)
✓	Klein et al., "Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands. Influence of DNA-heterodimer interactions," <u>J. Biol. Chem.</u> 275:19401-19408 (2000)

EXAMINER 	DATE CONSIDERED 11-25-02
---	-----------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Form PTO 1449	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4528	SERIAL NO. 09/814,604
			APPLICANT: Klein et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: March 22, 2001	GROUP: 1653


<i>[initials]</i>	Klein et al., "Identification and Functional Separation of Retinoic Acid Receptor Neutral Antagonists and Inverse Agonists," <u>J. Biol. Chem.</u> 271:22692-22696 (1996)
<i>[initials]</i>	Kodera et al., "Ligand type-specific Interactions of Peroxisome Proliferator-activated Receptor γ with Transcriptional Coactivators," <u>J. Biol. Chem.</u> 275:33201-33204 (2000)
<i>[initials]</i>	Korzus et al., "Transcription factor-specific requirements for coactivators and their acetyltransferase functions," <u>Science</u> 279:703-707 (1998)
<i>[initials]</i>	Kumar et al., "The structure of the nuclear hormone receptors" <u>Steroids</u> 64:310-319 (1999)
<i>[initials]</i>	Kurokawa et al., "Polarity-specific activities of retinoic acid receptors determined by a co-repressor," <u>Nature</u> 377:451-454 (1995)
<i>[initials]</i>	Kurokawa et al., "Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding," <u>Nature</u> 371:528-531 (1994)
<i>[initials]</i>	Lavinsky et al., "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes," <u>Proc. Natl. Acad. Sci.</u> 95:2920-2925 (1998)
<i>[initials]</i>	Lin et al., "Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers," <u>Mol. Cell</u> 5:821-30 (2000)
<i>[initials]</i>	Mangelsdorf et al., "The nuclear receptor superfamily: the second decade," <u>Cell</u> 83:835-839 (1995)
<i>[initials]</i>	McInerney et al., "Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation," <u>Genes Dev.</u> 12:3357-3368 (1998)

EXAMINER <i>[signature]</i>	DATE CONSIDERED 11/25/02
-----------------------------	--------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office 	ATTY DOCKET NO: P-AR 4528	SERIAL NO. 09/814,604
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Klein et al.	
	FILING DATE: March 22, 2001	GROUP: 1653

<i>J</i>	Mouchon et al., "Allosteric regulation of the discriminative responsiveness of retinoic acid receptor to natural and synthetic ligands by retinoid X receptor and DNA," <u>Mol. Cell. Biol.</u> 19:3073-3085 (1999)
<i>J</i>	Nagpal and Chandraratna "Retinoids as Anti-Cancer Agents," <u>Current Pharm. Design</u> 2:295-316 (1996)
<i>J</i>	Nagpal et al., "Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha," <u>J. Biol. Chem.</u> 270:923-927 (1995)
<i>J</i>	Nagy et al., "Mechanism of corepressor binding and release from nuclear hormone receptors," <u>Genes Dev.</u> 13:3209-3216 (1999)
<i>J</i>	Onate et al., "Sequence and characterization of a coactivator for the steroid hormone receptor superfamily," <u>Science</u> 270:1354-1357 (1995)
<i>J</i>	Perissi et al., "Molecular determinants of nuclear receptor-corepressor interaction," <u>Genes Devel.</u> 13:3198-3208 (1999)
<i>J</i>	Rachez et al., "Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex," <u>Nature</u> 398:824-828 (1999)
<i>J</i>	Safer et al., "Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone," <u>J. Biol. Chem.</u> 273:30175-82 (1998)
<i>J</i>	Spencer et al., "Steroid receptor coactivator-1 is a histone acetyltransferase," <u>Nature</u> 389:194-198 (1997)
<i>J</i>	Thacher et al., "Therapeutic Applications for Ligands of Retinoid Receptors," <u>Current Pharm. Design</u> 6:25-58 (2000)
<i>J</i>	Vanden Berghe et al., "Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor- κ B-dependent mechanism," <u>Mol. Pharmacol.</u> 56:797-806 (1999)

EXAMINER 	DATE CONSIDERED 1/25/02
--	-----------------------------------






EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED

JUN 28 2001
TECH CENTER 1600/2900

Page 5 of 5

Form PTO A449 JUN 25 2001 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4528	SERIAL NO. 09/814,604
		APPLICANT: Klein et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 22, 2001	GROUP: 1653

	Wagner et al., "The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins" <u>Endocrinology</u> 140:1449-58 (1999)
	Whitfield et al., "Steroid Hormone Receptors: Evolution, Ligands and Molecular Basis of Biologic Function," <u>J. Cell. Biochem. Suppl.</u> 32/33:110-122 (1999)
	Xu et al., "Coactivator and corepressor complexes in nuclear receptor function," <u>Curr. Opin. Genetics and Dev.</u> 9:140-147 (1999)
	Zhang et al., "A novel role for helix 12 of retinoid X receptor in regulating repression," <u>Mol. Cell Biol.</u> 9:6448-57 (1999)
	Zhu et al., "Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor," <u>J. Biol. Chem.</u> 272:25500-25506 (1997)

EXAMINER 	DATE CONSIDERED 11-20-02
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609;- Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.